Cord blood boost: new hope for tough myeloma cases?
NCT ID NCT03441958
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new way to treat high-risk multiple myeloma using umbilical cord blood that was expanded in the lab with a molecule called UM171. Nineteen patients received this special transplant to see if it was safe and could help control the disease. The goal is to improve outcomes while reducing side effects like graft-versus-host disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ECT-001 (UM171) expanded cord blood
What this could lead to
If successful, this approach could offer a safer and more effective transplant option for high-risk multiple myeloma patients, potentially improving long-term disease control.
What could go wrong
This is an early-phase trial with only 19 participants, so results may not apply broadly. Risks include graft-versus-host disease, infections, and disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIUSSS de l'Est-de-l'île-de-Montréal, Installation Hôpital Maisonneuve Rosemond
Montreal, Quebec, H1T2M4, Canada